GHDX to Show Prostate Test Result - Analyst Blog
April 05 2013 - 12:15PM
Zacks
Keeping in line with its strategy
to launch its prostate cancer test by the first half of 2013,
Genomic Health, Inc. (GHDX) set a presentation at
the American Urological Association ("AUA"), scheduled on May 8,
2013. Here the company will demonstrate complete results from the
positive clinical validation study of its biopsy-based Oncotype DX
prostate cancer test.
The company stated that the
presentation will include the results of previously conducted
development studies led by Cleveland Clinic based on 700 patients
and 700 candidate genes, which were needed to select the required
genes for this test. The company is currently making efforts to
launch this Oncotype DX Genomic Prostate Score (GPS) by the end of
the second quarter of 2013.
We note that, earlier in September,
the company announced positive results from a large clinical
validation study of GPS. The study, which was performed in
collaboration with prostate cancer researchers of the University of
California, demonstrated that the multi-gene OncotypeDX GPS
assessed in prostate needle biopsy tumor tissue is a predictor of
adverse pathology for patients with early-stage prostate cancer.
The study supported the results of six earlier feasibility and
development studies performed in collaboration with the Cleveland
Clinic.
We believe that with the commercial
launch, GPS will create a sizable impact on the market as prostate
cancer is among the most common types of cancers. According to the
2012 data, 900,000 people worldwide were diagnosed with prostate
cancer and based upon the results of prostate-specific antigen
(PSA) testing, biopsies were performed on over one million men in
the U.S., out of which 240,000 were diagnosed with prostate
cancer.
As a global cancer company, Genomic
Health is focused on the development and commercialization of
genomic-based clinical tests for cancer diagnosis that enables
physicians to make customized treatment decisions. The company
strongly believes that the launch of the prostate cancer test will
further strengthen its advanced next generation sequencing (NGS)
platform and accelerate the development of the future tests.
Genomic Health carries a Zacks Rank
#3 (Hold). Other medical device stocks worth a look are
Given Imaging (GIVN), Medical Action
Industries Inc. (MDCI) and Cytokinetics
Incorporated (CYTK). All the stocks carry a Zacks Rank #1
(Strong Buy).
CYTOKINETCS INC (CYTK): Free Stock Analysis Report
GENOMIC HEALTH (GHDX): Free Stock Analysis Report
GIVEN IMAGING (GIVN): Free Stock Analysis Report
MEDICAL ACTION (MDCI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Jul 2023 to Jul 2024